| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/18/2002 | US20020044924 Extracorporeal treatment of the patient's blood cells to induce apoptosis and administration of the apoptotic bodies and/or cells to patient; T-cell- mediated and inflammatory disorders |
| 04/18/2002 | DE10140028A1 Verfahren zur Herstellung von Citalopram A process for the preparation of citalopram |
| 04/18/2002 | DE10050663A1 Use of amino-substituted imidazo(1,2-a)pyridine, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine derivatives as NO synthase inhibitors, e.g. in treatment of migraine and neurodegenerative diseases |
| 04/18/2002 | DE10050662A1 New substituted dihydropyrido-pyrimidine derivatives, useful for treating e.g. pain, urinary incontinence and tinnitus |
| 04/18/2002 | DE10050661A1 New substituted 3,4-dihydro-pyrimido(1,2-a)pyrimidine and 3,4-dihydro-pyrazino(1,2-a)pyrimidine derivatives useful for the treatment of pain, urinary incontinence, pruritis, tinnitus and diarrhea |
| 04/18/2002 | CA2459746A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
| 04/18/2002 | CA2427499A1 Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents |
| 04/18/2002 | CA2425818A1 Novel human beta2 integrin alpha subunit |
| 04/18/2002 | CA2425771A1 Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 04/18/2002 | CA2425767A1 Lipocalins |
| 04/18/2002 | CA2425678A1 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425674A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425672A1 Use of substituted imidazo[1,2-a]-pyridin-,pyrimidin-and -pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting nos |
| 04/18/2002 | CA2425666A1 Substituted 3.4-dihydro-pyrido[1,2-a]pyrimidines |
| 04/18/2002 | CA2425650A1 Methods for the treatment of a traumatic central nervous system injury |
| 04/18/2002 | CA2425632A1 Agents for the treatment of viral infections |
| 04/18/2002 | CA2425610A1 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | CA2425593A1 Uridine therapy for patients with elevated purine levels |
| 04/18/2002 | CA2425540A1 Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]piperazine.hydrochloride |
| 04/18/2002 | CA2425520A1 N-alkylglycine trimeres capable of blocking the response to chemical substances, heat stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres |
| 04/18/2002 | CA2425187A1 Detection of neurodegenerative disorders |
| 04/18/2002 | CA2425121A1 Ether compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425001A1 Novel serine protease genes related to dppiv |
| 04/18/2002 | CA2424992A1 Paramyxovirus vectors for introducing foreign genes into skeletal muscle |
| 04/18/2002 | CA2424983A1 Nucleic acid molecules and polypeptides for immune modulation |
| 04/18/2002 | CA2424951A1 Beta-amino acid derivatives as integrin receptor antagonists |
| 04/18/2002 | CA2424812A1 Benzodiazepine derivatives as inhibitors of gamma secretase |
| 04/18/2002 | CA2424802A1 Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same |
| 04/18/2002 | CA2424292A1 Tricyclic compounds and uses thereof |
| 04/18/2002 | CA2424107A1 Sulfonylguanidines |
| 04/18/2002 | CA2423935A1 Substituted c-cyclohexylmethylamine derivatives |
| 04/18/2002 | CA2394084A1 Inhibitors of protein kinases |
| 04/17/2002 | EP1197554A1 Proliferation differentiation factor |
| 04/17/2002 | EP1197550A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 04/17/2002 | EP1197226A1 Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| 04/17/2002 | EP1197220A2 Therapeutic methods and compositions based on delta proteins and nucleic acids |
| 04/17/2002 | EP1196635A2 Cell death related drug targets in yeast and fungi |
| 04/17/2002 | EP1196609A2 Catalytically active recombinant memapsin and methods of use thereof |
| 04/17/2002 | EP1196577A2 Cell cycle and proliferation proteins |
| 04/17/2002 | EP1196575A2 Gtp-binding protein associated factors |
| 04/17/2002 | EP1196574A2 Human proteins involved in detoxification |
| 04/17/2002 | EP1196569A2 Electron transfer proteins |
| 04/17/2002 | EP1196568A1 Human lim domain proteins |
| 04/17/2002 | EP1196567A2 Human immune response molecules |
| 04/17/2002 | EP1196560A1 Neurotrophic factor receptor gfr-alpha-4 |
| 04/17/2002 | EP1196448A2 Homomeric and heteromeric ampa receptors |
| 04/17/2002 | EP1196442A1 Vgf polypeptides and methods of treating vgf-related disorders |
| 04/17/2002 | EP1196441A1 Keratinocyte growth factor-2 |
| 04/17/2002 | EP1196440A2 Therapeutic peptides derived from subsequences of bpi |
| 04/17/2002 | EP1196419A1 Potassium channel blocking agents |
| 04/17/2002 | EP1196417A1 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION |
| 04/17/2002 | EP1196414A1 Prodrugs of carbamate inhibitors of impdh |
| 04/17/2002 | EP1196411A1 Bradykinin b1 receptor antagonists |
| 04/17/2002 | EP1196407A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors |
| 04/17/2002 | EP1196404A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 04/17/2002 | EP1196403A1 Antipsychotic cyclic n-aralkyl amines |
| 04/17/2002 | EP1196400A1 Amino-alkyl derivatives |
| 04/17/2002 | EP1196397A1 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| 04/17/2002 | EP1196395A1 Cyclized amino acid derivatives |
| 04/17/2002 | EP1196391A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 04/17/2002 | EP1196390A2 Pyrazole compositions useful as inhibitors of erk |
| 04/17/2002 | EP1196389A1 N-heterocyclic derivatives with neuronal activity |
| 04/17/2002 | EP1196387A1 Azo amino acid derivatives for the treatment of neurological diseases |
| 04/17/2002 | EP1196386A2 N-substituted glycine derivatives |
| 04/17/2002 | EP1196385A1 Beta-amino acid derivatives for the treatment of neurological diseases |
| 04/17/2002 | EP1196380A2 Indoles and indazoles for the treatment of migraine |
| 04/17/2002 | EP1196373A1 3-amino-2-benzyl-1-phenyl-propane derivatives |
| 04/17/2002 | EP1196186A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 04/17/2002 | EP1196183A2 Oregano-based therapeutic composition |
| 04/17/2002 | EP1196176A1 Use of beta-napthoquinone for making medicines having an inhibiting effect on the release of glutamate by the brain |
| 04/17/2002 | EP1196174A1 Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis |
| 04/17/2002 | EP1196172A2 Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders |
| 04/17/2002 | EP1196170A2 New use of a macrolide compound for treating neurodegenerative disorders |
| 04/17/2002 | EP1196167A1 Method of reducing neuronal injury or apoptosis |
| 04/17/2002 | EP1196166A1 Azetidine carboxamide derivatives for the treatment of cns disorders |
| 04/17/2002 | EP1196165A2 Azetidine compounds in cns and eye diseases |
| 04/17/2002 | EP1196160A1 A synergistic combination: gabapentin and pregabalin |
| 04/17/2002 | EP1196156A2 Transnasal anticonvulsive compositions and modulated process |
| 04/17/2002 | EP1196147A1 Oral liquid compositions |
| 04/17/2002 | EP1196135A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/17/2002 | EP1196129A1 Method for scavenging radicals with urocanic acid, derivatives and analogues |
| 04/17/2002 | EP1196083A1 Imaging the dopamine transporter to determine ad-hd |
| 04/17/2002 | EP1196047A1 Prophylactic dietary supplement based on milk |
| 04/17/2002 | EP1007561B1 Novel conjugates of opioids and endogenous carriers |
| 04/17/2002 | EP0996620B1 Novel compounds |
| 04/17/2002 | EP0968212B1 Method of making (1s, 4r)-1-azabicyclo 2.2.1]heptan-3-one and (1r, 4s), 1-azabicyclo 2.2.1]heptan-3-one |
| 04/17/2002 | EP0956010B1 Pharmaceutical microspheres of valproic acid for oral administration |
| 04/17/2002 | EP0937038B1 Vitamin d analogues |
| 04/17/2002 | EP0934290B1 Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same |
| 04/17/2002 | EP0912086A4 Regulation of alzheimer's disease related proteins and uses thereof |
| 04/17/2002 | EP0888313B1 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors |
| 04/17/2002 | EP0804186B1 Indole diterpene alkaloid compounds |
| 04/17/2002 | EP0734385B1 Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging agents for neurodegenerative disorders |
| 04/17/2002 | EP0706395B1 Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade |
| 04/17/2002 | EP0662827B1 Diagnostic methods and pharmaceutical compositions based on notch proteins and nucleic acids |
| 04/17/2002 | EP0623146B1 Compositions and methods for inhibiting beta-protein function |
| 04/17/2002 | EP0359783B2 Treatment of autoimmune diseases by oral administration of autoantigens |
| 04/17/2002 | CN1345335A Melanocortin receptor ligands |
| 04/17/2002 | CN1345332A C-terminal modified (N-substituted)-2 indolylcarbonyldiptides as inhibitors of ICE/CED-3 family of cysteine proteases |
| 04/17/2002 | CN1345329A Tumor mecrosis factor receptors 6 alpha and beta |